Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New light device could spot skin cancer without a scalpel

NCT ID NCT02956265

Diagnosis Sponsor: Centre Hospitalier Régional Metz-Thionville Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a non-invasive device that uses light to classify skin lesions as healthy, actinic keratosis, or carcinoma. Researchers aimed to see if it could help doctors diagnose skin conditions more accurately without needing a biopsy. The study involved 142 adults with suspicious skin lesions, and the device was gently placed on the skin to capture optical signals.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
bimodal optical spectroscopy device
What this could lead to
If successful, this device could help doctors accurately identify skin lesions without a biopsy, reducing unnecessary surgeries and scarring.
What could go wrong
This is a completed early-stage study with 142 participants, so results may not apply to all skin types or lesions. The device is not yet proven to replace standard diagnosis.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

142 people

The number who actually took part.

Start date

Oct 2016

Finished

Mar 2021

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adults, and * Autonomous: enjoying full citizenship rights and full mental abilities, and * Affiliated to a social security system, and * Suffering from carcinomatous or polymorphous skin lesions that can be fully managed in an outpatient (ambulatory) surgery procedure. Exclusion Criteria: * Carcinomatous or polymorphous skin lesions that require day admission, or * Carcinomatous or polymorphous skin lesions for which resection margins are uncertain, or * Naevomatous skin lesions and related skin pathologies.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Actinic keratosis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

actinic keratosis in situ carcinoma invasive carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Carcinomatous or polymorphous skin lesions

Contacts and locations

Locations

  • CHR Metz Thionville

    Metz, 57085, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.